Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis
Konstantinos Papamichael, Niels Vande Casteele, Jenny Jeyarajah, et al.
The American Journal of Gastroenterology (2020) Vol. 116, Iss. 5, pp. 1007-1014
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Peter M. Irving, K Gecse
Gastroenterology (2022) Vol. 162, Iss. 5, pp. 1512-1524
Open Access | Times Cited: 73
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
Michel Adamina, Silvia Minozzi, Janindra Warusavitarne, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 23
Management of Perianal Fistulizing Crohn's Disease According to Principles of Wound Repair
Jeffrey D. McCurdy, Imogen Hartley, Corina Behrenbruch, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Management of Perianal Crohn's Disease
Alyssa Parian, Megan Obi, Phillip Fleshner, et al.
The American Journal of Gastroenterology (2023) Vol. 118, Iss. 8, pp. 1323-1331
Open Access | Times Cited: 25
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
Thanaboon Chaemsupaphan, Rupert W. Leong, Niels Vande Casteele, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1234-1243
Open Access | Times Cited: 8
Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
Pascal Juillerat, Maude Martinho Grueber, Roseline Ruetsch, et al.
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100104-100104
Open Access | Times Cited: 27
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
Esteban Fuentes-Valenzuela, Francisco Javier García‐Alonso, Carlos Maroto-Martín, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1586-1593
Closed Access | Times Cited: 20
Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies
Jalpa Devi, David H. Ballard, Tina Aswani-Omprakash, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 48-63
Closed Access | Times Cited: 6
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Perianal disease in inflammatory bowel disease: Broadening treatment and surveillance strategies for anal cancer
Tatiana Pacheco, Sara Monteiro, Luísa Barros, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 28, pp. 3373-3385
Open Access | Times Cited: 5
A new protocolised treatment strategy optimising medical and surgical care leads to improved healing of Crohn’s perianal fistulas
Michael De Gregorio, Leon Shin‐han Winata, Imogen Hartley, et al.
Journal of Crohn s and Colitis (2025)
Closed Access
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Management of Perianal Fistulizing Crohn’s Disease
Arshdeep Singh, Vandana Midha, Gursimran Kochhar, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 9, pp. 1579-1603
Closed Access | Times Cited: 14
Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
Jiayin Yao, Heng Zhang, Tao Su, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 939-939
Open Access | Times Cited: 12
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 11, pp. 3045-3045
Open Access | Times Cited: 18
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients
Andrea Pascual-Oliver, Diego Casas Deza, Camila Cuarán, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 6, pp. 922-929
Closed Access | Times Cited: 11
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
Fernando Magro, María Manuela Estevinho, Gaia Catalano, et al.
United European Gastroenterology Journal (2023) Vol. 11, Iss. 6, pp. 531-541
Open Access | Times Cited: 9
Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management
Sulak Anandabaskaran, L Hanna, Nusrat Iqbal, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6379-6379
Open Access | Times Cited: 8
Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Camilla de Almeida Martins, Karoline Soares Garcia, Natália Sousa Freitas Queiroz
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn’s Disease
Dongxing Cao, Keyu Qian, Ying Zhao, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 4, pp. 580-592
Closed Access | Times Cited: 12
Infliximab for medical induction of remission in Crohn's disease
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, et al.
Cochrane library (2023) Vol. 2023, Iss. 12
Open Access | Times Cited: 7
Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
Eric Cheah, James Guoxian Huang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 10, pp. 1539-1550
Open Access | Times Cited: 6
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top